The group’s restructuring, C-suite clearout and refocusing on bemarituzumab is rewarded with a $1.9bn buyout by Amgen.
Survival data with bemarituzumab see the company erase half of the past three years’ losses.
Among late-breaking abstracts whose titles have just gone live two mechanisms have a chance to redeem themselves.
Mirati Therapeutics nearly stole the show at Asco despite not actually presenting – a fact that illustrates how low on meaningful data this year's conference was.
Discontinuations and an unusual revelation about Tecentriq’s breast cancer data dominated the R&D part of the company’s third-quarter results call.